Safety and Tolerability of Nintedanib in Patients with Fibrosing Interstitial Lung Diseases: Post-marketing Data
Post-marketing safety data on established and potential adverse events associated with nintedanib in patients with fibrosing ILDs, collected over 9 years, demonstrated a safety profile that was similar to that established in clinical trials and provided in the product labels. Education of patients about the adverse events that may be associated with nintedanib, and the effective management of adverse events when they occur, is important to minimise the impact of adverse events and help patients remain on treatment.
Authors
- Ivana Ritter (ORCID: https://orcid.org/0000-0003-1940-2440)
- Nazia Chaudhuri (ORCID: https://orcid.org/0000-0003-3325-6996)
- Arata Azuma (ORCID: https://orcid.org/0000-0003-0506-9966)
- Kamila Sroka-Saidi
- Sergio Harari (ORCID: https://orcid.org/0000-0001-8629-7391)
- Elvira Erhardt (ORCID: https://orcid.org/0000-0003-3885-1479)
Institutions
- Boehringer Ingelheim (Germany) (DE)
- University of Ulster (GB)
- University of Milan (IT)
- MultiMedica (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Nobuhara Hospital (JP)
- Nippon Medical School (JP)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1007/s12325-024-03023-4
- Citations
- 8
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 3.35